EyePoint, Inc. (EYPT) Spending and interest coverage
- R&D / revenue · 12 months: Value 9423.39%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1263.02%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 9423.39% | Research and development expense / revenue. Period ending 2026-06-30. $262.72M ÷ $2.79M × 100 ≈ 9423.39% |
| Stock-based compensation / revenue · 12 months | 1263.02% | Share-based compensation / revenue. Period ending 2026-06-30. $35.21M ÷ $2.79M × 100 ≈ 1263.02% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 262.72M USD | Research and Development Expense |
| Revenue | 2.79M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 35.21M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -316.98M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $262.72M | $2.79M | $35.21M | $-316.98M | (m) | 9423.39% | 1263.02% | (m) | (m) |
| 2026-03-31 | $234.61M | $7.61M | $31.69M | $-281.82M | (m) | 3081.34% | 416.22% | (m) | (m) |
| 2025-12-31 | $221.04M | $31.37M | $27.87M | $-243.43M | (m) | 704.60% | 88.85% | (m) | (m) |
| 2025-09-30 | $205.20M | $42.34M | $29.02M | $-218.33M | (m) | 484.65% | 68.55% | (m) | (m) |
| 2025-06-30 | $186.99M | $51.90M | $30.04M | $-189.05M | (m) | 360.30% | 57.89% | (m) | (m) |
| 2025-03-31 | $161.36M | $56.04M | $31.86M | $-161.37M | (m) | 287.93% | 56.85% | (m) | (m) |
| 2024-12-31 | $132.93M | $43.27M | $36.74M | $-145.85M | (m) | 307.18% | 84.90% | (m) | (m) |
| 2024-09-30 | $107.50M | $45.71M | $32.43M | $-116.97M | (m) | 235.17% | 70.94% | (m) | (m) |
| 2024-06-30 | $95.33M | $50.39M | $28.61M | $-98.62M | $0.00 | 189.17% | 56.78% | (m) | Reported |
| 2024-03-31 | $81.18M | $50.02M | $21.71M | $-86.83M | $435.00K | 162.30% | 43.40% | -199.62× | Reported |
| 2023-12-31 | $64.66M | $46.02M | $12.06M | $-75.07M | $1.25M | 140.51% | 26.20% | -60.20× | Reported |
| 2023-09-30 | $62.25M | $42.52M | $11.83M | $-102.45M | $2.03M | 146.40% | 27.82% | -50.52× | Reported |
| 2023-06-30 | $56.05M | $37.33M | $11.40M | $-106.45M | $2.69M | 150.14% | 30.53% | -39.56× | Reported |
| 2023-03-31 | $53.31M | $39.79M | $13.75M | $-102.91M | $2.81M | 133.98% | 34.55% | -36.66× | Reported |
| 2022-12-31 | $49.64M | $41.40M | $14.18M | $-99.64M | $3.19M | 119.90% | 34.24% | -31.24× | Reported |
| 2022-09-30 | $43.02M | $42.41M | $13.62M | $-73.95M | $3.80M | 101.42% | 32.12% | -19.48× | Reported |
| 2022-06-30 | $40.35M | $41.46M | $12.90M | $-70.86M | $4.52M | 97.33% | 31.10% | -15.67× | Reported |
| 2022-03-31 | $32.97M | $38.91M | $9.94M | $-62.63M | $5.35M | 84.72% | 25.54% | -11.71× | Reported |
| 2021-12-31 | $28.50M | $36.94M | $7.45M | $-55.28M | $5.50M | 77.15% | 20.16% | -10.05× | Reported |
| 2021-09-30 | $24.79M | $32.53M | $5.90M | $-49.96M | $5.94M | 76.21% | 18.15% | -8.42× | Reported |
| 2021-06-30 | $20.38M | $39.16M | $5.82M | $-36.61M | $6.39M | 52.04% | 14.86% | -5.73× | Reported |
| 2021-03-31 | $18.05M | $34.27M | $5.38M | $-36.78M | $6.82M | 52.67% | 15.68% | -5.39× | Reported |
| 2020-12-31 | $17.42M | $34.44M | $5.55M | $-37.29M | $7.26M | 50.60% | 16.11% | -5.14× | Reported |
| 2020-09-30 | $16.35M | $35.94M | $5.14M | $-33.54M | $7.22M | 45.49% | 14.30% | -4.65× | Reported |
| 2020-06-30 | $15.74M | $22.75M | $3.73M | $-45.64M | $7.15M | 69.19% | 16.39% | -6.39× | Reported |
| 2020-03-31 | $16.42M | $25.84M | $4.49M | $-44.65M | $6.94M | 63.56% | 17.37% | -6.43× | Reported |
| 2019-12-31 | $15.37M | $20.36M | $4.57M | $-47.86M | $6.18M | 75.46% | 22.43% | -7.75× | Reported |
| 2019-09-30 | $15.41M | $14.17M | $4.86M | $-49.88M | $5.22M | 108.76% | 34.32% | -9.56× | Reported |
| 2019-06-30 | $18.16M | $12.15M | $5.28M | $-49.38M | $4.26M | 149.50% | 43.49% | -11.59× | Reported |
| 2019-03-31 | (m) | $5.66M | (m) | $-48.99M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $18.50M | $4.57M | $3.97M | $-39.02M | (m) | 404.77% | 86.79% | (m) | (m) |
| 2018-09-30 | $18.59M | $3.06M | $3.42M | $-33.82M | $1.53M | 607.18% | 111.69% | -22.03× | Reported |
| 2018-06-30 | $16.18M | $2.96M | $2.70M | $-26.27M | $720.00K | 546.37% | 91.32% | -36.49× | Reported |
| 2018-03-31 | $15.63M | $2.95M | $2.41M | $-22.63M | (m) | 530.23% | 81.85% | (m) | (m) |
| 2017-12-31 | $15.63M | $2.61M | $2.61M | $-23.11M | (m) | 598.89% | 100.15% | (m) | (m) |
| 2017-09-30 | $14.52M | $7.65M | $2.40M | $-17.40M | (m) | 189.89% | 31.42% | (m) | (m) |
| 2017-06-30 | $14.88M | $7.54M | $2.46M | $-18.58M | (m) | 197.37% | 32.58% | (m) | (m) |
| 2017-03-31 | $14.77M | $7.14M | $2.39M | $-18.90M | (m) | 206.82% | 33.44% | (m) | (m) |
| 2016-12-31 | $14.52M | $6.88M | $2.40M | $-18.83M | (m) | 211.18% | 34.98% | (m) | (m) |
| 2016-09-30 | $15.08M | $1.43M | $2.49M | $-23.98M | (m) | 1053.60% | 174.14% | (m) | (m) |
| 2016-06-30 | $14.38M | $1.62M | $2.16M | $-21.77M | (m) | 887.72% | 133.52% | (m) | (m) |
| 2016-03-31 | $13.47M | $1.73M | $2.17M | $-20.52M | (m) | 781.16% | 125.80% | (m) | (m) |
| 2015-12-31 | $13.74M | $1.73M | $2.12M | $-20.47M | (m) | 794.68% | 122.79% | (m) | (m) |
| 2015-09-30 | $12.79M | $1.72M | $2.06M | $-19.35M | (m) | 741.65% | 119.32% | (m) | (m) |
| 2015-06-30 | $12.09M | $26.57M | $1.96M | $6.42M | (m) | 45.50% | 7.38% | (m) | (m) |
| 2015-03-31 | $11.20M | $26.45M | $1.79M | $7.61M | (m) | 42.33% | 6.76% | (m) | (m) |
| 2014-12-31 | $10.13M | $28.11M | $1.61M | $10.44M | (m) | 36.02% | 5.74% | (m) | (m) |
| 2014-09-30 | $9.85M | $28.18M | $1.50M | $11.02M | (m) | 34.96% | 5.33% | (m) | (m) |
| 2014-06-30 | $9.57M | $3.47M | $1.41M | $-13.49M | (m) | 275.64% | 40.63% | (m) | (m) |
| 2014-03-31 | $9.59M | $3.67M | $1.36M | $-13.46M | (m) | 261.01% | 37.08% | (m) | (m) |
| 2013-12-31 | $8.90M | $2.19M | $1.23M | $-14.05M | (m) | 405.88% | 56.20% | (m) | (m) |
| 2013-09-30 | $7.99M | $2.19M | $1.19M | $-13.16M | (m) | 365.16% | 54.46% | (m) | (m) |
| 2013-06-30 | $7.00M | $2.14M | $1.32M | $-12.03M | (m) | 326.88% | 61.46% | (m) | (m) |
| 2013-03-31 | $6.09M | $2.35M | $1.31M | $-10.36M | (m) | 259.36% | 55.66% | (m) | (m) |
| 2012-12-31 | $6.02M | $2.38M | $1.38M | $-10.28M | (m) | 253.31% | 57.89% | (m) | (m) |
| 2012-09-30 | $6.43M | $2.42M | $1.28M | $-25.27M | (m) | 265.83% | 52.77% | (m) | (m) |
| 2012-06-30 | $7.04M | $3.53M | $1.41M | $-25.21M | (m) | 199.63% | 40.02% | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $6.86M | $4.96M | $2.05M | $-10.00M | (m) | 138.25% | 41.33% | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $6.99M | $23.05M | $1.50M | $9.09M | (m) | 30.34% | 6.49% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |